Elacestrant NEW
| Price | $126 | $247 | $396 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Elacestrant | CAS No.: 722533-56-4 |
| Purity: 99.92% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Elacestrant |
| Description | Elacestrant (RAD1901) with IC50s of 48 and 870 nM for ERα and ERβ, respectively.Elacestrant ?is an orally available selective estrogen receptor degrader . |
| In vitro | Elacestrant treatment exhibits dose-dependent inhibition of ERα expression, with an EC50 of 0.6 nM.Treatment of ER-positive MCF-7 cells with E2 results in a potent and dose-dependent increase in proliferation, with an EC50 of 4 pM.Treatment of cells with Elacestrant in the presence of 10 pM E2 resultsin a dose-dependent decrease in proliferation, with an IC50 value of 4.2 nM.Elacestrant selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. |
| In vivo | Elacestrant produces a robust and profound inhibition of tumor growth in MCF-7 xenograft models.Elacestrant preserves ovariectomy-induced bone loss and preventes the uterotropic effects of E2.Elacestrant-treated animals survived longer than those treated with either control or fulvestrant. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 150 mg/mL (327.06 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.72 mM), Sonication is recommended. |
| Keywords | RAD-1901 | RAD 1901 | progestogenReceptor | progestogen Receptor | Inhibitor | inhibit | EstrogenReceptor | Estrogen Receptor/ERR | Estrogen Receptor | ERβ | ERα | ERR | Elacestrant |
| Inhibitors Related | Tamoxifen | Mifepristone | Estradiol | Astragaloside IV | Bisphenol B | Bisphenol Z | Mequinol | Phthalic acid | Ethisterone | Alpha-Estradiol | Ferrous Bisglycinate | Cholesterol |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Toxic Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:36799-17-4
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-30 | ||
| $122.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-05 | |
|
VIP5Y
|
Shanghai Joiny Pharmaceutical Co.,LTD
|
2025-11-19 | ||
| $126.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY